Page 15 - TD-3-4

Tumor Discovery Expert consensus of NUT carcinoma

3. Results 3.1.3. Patient TNM classification of malignant tumors
staging
3.1. Patient characteristics
Among NUT carcinoma patients with a known TNM
As compiled from the literature, the distribution and stage, 50.9% (56/110) were at stage IV, and 33.6%
general characteristics of NUT carcinoma patients are
summarized in Figure 1. Additional patient details are (37/110) were at stage III. In thoracic NUT carcinoma
provided in Table S5. patients, the proportion of those at stage III (36.36%,
24/66) and stage IV (53.03%, 35/66) was higher than in
3.1.1. Patient gender head-neck NUT carcinoma patients, whereas 26.32%
This study evaluated 526 patients from 199 articles; no (10/38) were at stage III and 47.37% (18/38) were at
significant difference was observed in the gender ratio stage IV.
among patients with known gender. The overall male- 3.1.4. Clinical symptoms at initial diagnosis of NUT
to-female ratio was 1.18 (276 males and 232 females). carcinoma in patients
In the thoracic group, the male-to-female ratio was
1.52 (144 males and 95 females), while in the head and A total of 24 clinical symptoms were identified by
neck group, the ratio was 0.97 (81 males and 83 females). combining data from the literature. Patients with thoracic
NUT carcinoma frequently present with non-specific
3.1.2. Patient distribution by region and age symptoms. Common clinical symptoms at the initial
Most patients were in the Americas (51.52%), followed by diagnosis of thoracic NUT carcinoma include cough
Asia (34.6%). The average age of all patients was 38 years. (56.45%, 70/124), pain (40.32%, 50/124), and dyspnea
Thoracic NUT carcinoma patients had a slightly higher (30.65%, 38/124). In contrast, patients with head-and-
average age of 40.02 years (range: 6 – 86 years) than head- neck NUT carcinoma primarily exhibited compression
and-neck NUT carcinoma patients, whose average age was symptoms due to tumor enlargement (53.01%, 44/83),
33.82 years (range: 1 – 82 years). pain (37.35%, 31/83), nasal congestion (14.46%, 12/83),

Figure 1. The distribution and general characteristics of nuclear protein of the testis carcinoma patients.
Note: The X-axis represents the specific indicators under each category, while the Y-axis indicates the percentage (%) of these indicators within the
corresponding category.
Abbreviations: BRD3: Bromodomain-containing protein 3; BRD4: Bromodomain-containing protein 4; Non.reg.lym.node: Non-regional lymph node;
NSD3: Nuclear receptor binding SET domain protein 3; NUTM1: Nuclear protein of the testis midline carcinoma family member 1.

Volume 3 Issue 4 (2024) 7 doi: 10.36922/td.4904